Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ashley Davila

Clinical Nurse Specialist, Medical-Surgical Austin, TX Clinical Nurse Specialist

NPI 1326054016 CMS profile 10443761

6500 North Mopac, Austin, TX 78731

Open in the dashboard

General payments

$1,266

58 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Davila of Austin, TX is reported in the CMS Open Payments database as having received $1,266 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Clinical Nurse Specialist, Medical-Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $662 24
2024 General $250 15
2023 General $123 7
2022 General $106 5
2021 General $125 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Davila
  • Clinical Nurse Specialist, Medical-Surgical median
  • Middle half of Clinical Nurse Specialist, Medical-Surgical
  • National median

In program year 2025, general payments to Ashley Davila were reported at $662. Among 59 Clinical Nurse Specialist, Medical-Surgical profiles paid that year, the median was $165 and the middle half received between $54 and $254.

Show as a table
Year Ashley Davila Clinical Nurse Specialist, Medical-Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $125 $214 $58–$714 $132
2022 $106 $153 $29–$560 $149
2023 $123 $119 $27–$460 $160
2024 $250 $124 $52–$304 $164
2025 $662 $165 $54–$254 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Rigel Pharmaceuticals, Inc. $340 13 payments
  2. Amgen Inc. $235 8 payments
  3. Abbott Laboratories $153 10 payments
  4. Novartis Pharmaceuticals Corporation $130 6 payments
  5. Regeneron Healthcare Solutions, Inc. $126 6 payments
  6. Sanofi-Aventis U.S. LLC $45 2 payments
  7. AbbVie, Inc. $38 2 payments
  8. Novo Nordisk Inc $37 2 payments
  9. Kyowa Kirin, Inc. $30 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $24 1 payment
  11. Other $109 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,226 54 payments
  2. Education $40 4 payments
Products named General payments · program years 2021–2025
  1. Tavalisse $340 13 payments
  2. Rezlidhia $340 13 payments
  3. Gavreto $321 12 payments
  4. REPATHA $134 1 payment
  5. FreeStyle Libre 3 $131 9 payments
  6. LEQVIO $130 6 payments
  7. EVKEEZA $126 6 payments
  8. PRALUENT $106 5 payments
  9. TEPEZZA $62 5 payments
  10. TZIELD $45 2 payments
  11. Other $329 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

797

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$209,503

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

37.8%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 108 $83,185
Praluent Pen Alirocumab Brand 29 $25,379
Ozempic Semaglutide Brand 20 $21,322
Rybelsus Semaglutide Brand 13 $21,152
Mounjaro Tirzepatide Brand 13 $20,518
Trulicity Dulaglutide Brand 11 $11,538
Vascepa Icosapent Ethyl Brand 26 $10,272
Synthroid Levothyroxine Sodium Brand 61 $5,786
Ezetimibe Generic 144 $2,831
Icosapent Ethyl Generic 11 $2,739

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$26,046

Medicare's payments for the services billed

Medicare patients

265

Average age 72

Services billed

365

217 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 43%
Ischemic heart disease 34%
Diabetes 33%
Osteoporosis 24%
Cancer 14%
Atrial fibrillation 12%
Heart failure 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $22
$22 — —
Korlym
  • Corcept Therapeutics $20
$20 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $20
$20 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $14
$14 — —
RYBELSUS
  • Novo Nordisk Inc $12
$12 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Medical-Surgical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record